Skip to main content

Table 3 Treatment and outcomes (n = 25)

From: Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment

Characteristic

Value

Hospitalization, n (%)

15 (60)

Duration of hospitalization, days (IQR)

7 (3–11)

Cholecystitis was the reason to stop ICI treatment, n (%)

3 (12)

Treatment, n (%)

 Intravenous fluid

17 (68)

 Antibiotics

18 (72)

 Steroids

5 (20)

 Surgical cholecystectomy

5 (20)

 Percutaneous drainage

8 (32)

Complications, n (%)

 Sepsis

2 (8)

 Perforation

4 (16)

Restarted ICI therapy after onset, n (%)

10 (40)

Recurrent cholecystitis symptoms, n (%)

0 (0)

Any-cause death, n (%)a

12 (48)

  1. aDeaths recorded were unrelated to cholecystitis. IQR interquartile range, ICI immune checkpoint inhibitor